Paratek Pharmaceuticals, Inc.
PRTK · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.01 | 0.05 | -0.15 |
| FCF Yield | -1.40% | 7.65% | -19.81% | -8.76% |
| EV / EBITDA | -37.48 | -23.05 | -132.68 | -23.05 |
| Quality | ||||
| ROIC | -8.81% | -13.43% | -2.12% | -16.86% |
| Gross Margin | 88.52% | 78.62% | 85.80% | 84.30% |
| Cash Conversion Ratio | 0.12 | -0.55 | 2.81 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | 20.06% | 46.11% | 51.32% | 41.95% |
| Free Cash Flow Growth | -116.06% | 154.88% | -62.24% | 14.35% |
| Safety | ||||
| Net Debt / EBITDA | -23.67 | -13.76 | -91.27 | -14.31 |
| Interest Coverage | -1.78 | -3.53 | -0.62 | -3.64 |
| Efficiency | ||||
| Inventory Turnover | 0.38 | 0.45 | 0.62 | 0.21 |
| Cash Conversion Cycle | 274.87 | 239.50 | 194.95 | 366.08 |